Human LEF1 Alexa Fluor® 350-conjugated Antibody

Applications

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Preparation and Storage

Background: LEF1

LEF1 (Lymphoid Enhancer-binding Factor 1) is a functionally diverse member of the TCF/LEF family of transcription factors. The name LEF1 was originally applied to the mouse factor, while its human counterpart was named TCF-1 alpha. Since there is a related molecule named TCF-1, to avoid confusion with TCF-1 alpha, both species factors are now called LEF1. Although its predicted MW is 44 kDa, it runs anomalously at 35-55 kDa in SDS-PAGE. LEF1 has restricted expression in adult, being limited to T cells, thymocytes, pre-B cells and NK cells. LEF1 demonstrates sequence-specific (CCTTTG[T/A][T/A]) DNA binding and directs beta -catenin to Wnt‑responsive genes. Either transcriptional activation or repression may occur on LEF1 target genes, depending upon 1) the cofactors recruited to the LEF1: beta ‑catenin complex, and 2) the phosphorylation state of LEF1. Human LEF1 is 399 amino acids (aa) in length. It contains one DNA-binding HMG-box (aa 298‑369), three potential phosphorylation sites, and an N-terminal SUMOylation site at Lys27. There are at least five isoform variants. One utilizes an alternative start site at Met116, a second contains a 47 aa substitution for aa 283‑299, and a third combines the previous two variations. A fourth variant shows a deletion of aa 214‑241, while a fifth variant combines the afore mentioned deletion of aa 214-241 with a 25 aa substitution for aa 390‑399. Over aa 120‑280, human LEF1 shares 97% aa sequence identity with mouse LEF1.

Product Datasheets

Related Research Areas

• Cancer Biomarkers
• High Mobility Group (HMG) Transcription Factors
• Transcription Factors in the Akt Pathway
• Wnt Signaling Modulators